Market

U.S. FDA approves Celltrion's OMLYCLO ® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR ®

U.S. FDA approves Celltrion's OMLYCLO ® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR ®
Read More

Related Posts

Autodesk says it’s cutting 9% of its workforce, and shares rise

Autodesk says it’s cutting 9% of its workforce, and sha...

Nvidia’s stock is in a funk. Earnings didn’t help, but here’s what could.

Nvidia’s stock is in a funk. Earnings didn’t help, but ...

Dell sees its backlog swell as big AI deals come through

Dell sees its backlog swell as big AI deals come through

Social Security Administration announces ‘massive’ reorganization, ‘significant’ job cuts

Social Security Administration announces ‘massive’ reor...

Csg Systems director Ronald Cooper sells $599,580 in stock

Csg Systems director Ronald Cooper sells $599,580 in stock

HP Inc. was proactive about the impact of tariffs, and it may be paying off

HP Inc. was proactive about the impact of tariffs, and ...